Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

AntibioticsDaptomycin6mg/kg IV QHDAdminister Post-HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
1620788.1N/A920.094.2-4.539-57.6 (high flux)


  • Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
  • Benziger D, Pertel P, Donovan J, Yankelev S, Schwab R. Pharmacokinetics and safety of multiple doses of daptomycin 6 mg / kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Clinical Nephrology 2011; 75(1), 63-69.
  • Burkhardt O, Kielstein J. A simplified three-times weekly daptomycin dosing regimen for chronic hemodialysis patients. Expert Review of Anti-Infective Therapy 2010; 8(1), 11.
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00080
  • Dvorchik B, Arbeit R, Chung J, Liu S, Knebel W, Kastrissios H. Population Pharmacokinetics of Daptomycin. Antimicrobial agents and chemotherapy 2004; 48(8), 2799-2807.
  • Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
  • Kielstein J, Eugbers C, Bode-Boeger S et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study. Nephrology, dialysis, transplantation (official publication of the European Dialysis and Transplant Association - European Renal Association) 2010; 25(5), 1537-41.
  • Mueller B, Crompton J, Donovan B, Yankalev S, Lamp K. Safety of daptomycin in patients receiving hemodialysis. Pharmacotherapy 2011; 31(7), 665-72.
  • Patel N, Cardone K, Grabe D et al. Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis. Antimicrobial agents and chemotherapy 2011; 55(4), 1677-83.
  • Salama N, Segal J, Churchwell M et al. Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clinical journal of the American Society of Nephrology (CJASN) 2009; 4(7), 1190-4.
  • Salama N, Segal J, Churchwell M et al. Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Nephrology, dialysis, transplantation (official publication of the European Dialysis and Transplant Association - European Renal Association) 2010; 25(4), 1279-84.